New cocktail of drugs could be effective in fighting kidney cancer : itv

As it stated in itv

New cocktail of drugs could be effective in fighting kidney cancer

New cocktail of drugs could be effective in fighting kidney cancer

A combination of two immunotherapy drugs may prove an effective new weapon against advanced kidney cancer, trial results show.Scientists found that 40% of patients treated with nivolumab and ipilimumab experienced a significant reduction in their tumour sizes.In a tenth of these patients, the cancer appeared to have disappeared altogether - there was no detectable sign of it.The CheckMate -016 study was an early Phase I trial mainly designed to investigate doses and side effects.


as well thejournal

New cocktail of drugs could significantly improve outcomes for cancer patients

New cocktail of drugs could significantly improve outcomes for cancer patients

A NEW COMBINATION of two drugs could extend the lives of thousands of people with kidney cancer.Scientists say 40% of kidney cancer patients using the combined drugs saw their tumours significantly reduce in size, while 10% were left with "no detectable sign of cancer" at all.The two drugs, ipilimumab and nivolumab, work by stimulating the body's own immune system to fight the cancer.The study evaluated the drugs, at different doses, in previously-treated and treatment-naïve patients with metastatic renal cell carcinoma.


coupled with express

Immune boosting drugs save kidney cancer patients

Immune boosting drugs save kidney cancer patients

Peter Waite was diagnosed with kidney cancer last year and was enrolled on the trialForty per cent of people in a UK trial saw their tumours shrink significantly and 10 per cent were freed of the disease.Professor John Wagstaff, a leading cancer specialist who has used the treatment, said: "These results are astounding and offer real hope of long-term remission."Karol Sikora, one of the country's leading cancer experts, said: "This is fantastic news and a real breakthrough.However, we now need to find a test that would predict which patients will respond to this treatment as it is very expensive."


in the same way statnews

The race to create a new class of ovarian cancer drugs heats up

The race to create a new class of ovarian cancer drugs heats up

The race to create the next potent ovarian cancer drug is coming to a head.Ovarian cancer has historically been one of the harder cancers to treat — but a promising new class of drugs, called PARP inhibitors, is proving powerful in delaying the growth of tumors by preventing cancer cells from repairing themselves after they've been damaged by chemotherapy.In recent days, the researchers behind three PARP drug contenders threw down preliminary data during the European Society for Medical Oncology conference in Denmark.article continues after advertisementMassachusetts-based Tesaro was the clear front-runner with its experimental once-a-day ovarian cancer pill, niraparib.